This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Immunomedics Announces Fiscal 2012 Results

The Company has no long-term debt and as of June 30, 2012, cash and cash equivalents totaled $32.8 million.

"We were successful implementing our non-dilutive financing strategies to support our robust R&D program in the 2012 fiscal year," commented Gerard G. Gorman, Senior Vice President Finance and Chief Financial Officer. "In fiscal 2013, expenditures are expected to be $24 to $26 million due to increased spending for research and development, including the further clinical development of clivatuzumab in patients with pancreatic cancer."

The Company's key clinical developments and future planned activities:


Epratuzumab tetraxetan

  • Initial Phase I results of yttrium-90-labeled epratuzumab tetraxetan combined with veltuzumab in patients with aggressive lymphoma were reported in an oral presentation at the 59 th Annual Meeting of the Society of Nuclear Medicine (SNM). (Please refer to the Company's press release at for more information)

Clivatuzumab tetraxetan

  • Full survival data from the Phase I/II frontline study of yttrium-90-labeled clivatuzumab tetraxetan combined with gemcitabine in advanced pancreatic cancer were reported at the 2012 Annual Meeting of the American Society of Clinical Oncology, the 59 th Annual Meeting of the SNM, and the 14 th World Congress on Gastrointestinal Cancer organized by the European Society of Medical. (Please refer to the Company's press release at for more information on the results of this trial)


  • During fiscal year 2012, Takeda-Nycomed reviewed future development plans for veltuzumab as a therapy for patients with rheumatoid arthritis (RA). A Phase II clinical trial is ongoing. Modifications to protocol design and the RA patient population for enrollment are being considered.


  • Also in the second half of 2012, we plan to launch a Phase I study of hRS7-SN-38, the third agent from our antibody-drug conjugate program to enter clinical trials, for the potential treatment of certain solid cancers. hRS7-SN-38 is a humanized anti-TROP-2 antibody attached with SN-38, the active metabolite of irinotecan, a chemotherapeutic drug approved for the treatment of patients with colorectal cancer.

Conference Call

The Company will host a conference call and live audio webcast on Friday, August 24, 2012 at 10:00 a.m. Eastern time to discuss financial results for the fourth quarter and fiscal year 2012, and review key clinical developments and future planned activities. To access the conference call, please dial (877) 303-2523 or (253) 237-1755 using the Conference ID 20050489. The conference call will be webcast via the Investors page on the Company's website at . Approximately two hours following the live event, a webcast replay of the conference call will be available on the Company's website for 30 days through September 23, 2012 .

About Immunomedics

Immunomedics is a New Jersey-based biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. We have developed a number of advanced proprietary technologies that allow us to create humanized antibodies that can be used either alone in unlabeled or "naked" form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins, in each case to create highly targeted agents. Using these technologies, we have built a pipeline of therapeutic product candidates that utilize several different mechanisms of action. We also have a majority ownership in IBC Pharmaceuticals, Inc., which is developing a novel DOCK-AND-LOCK™ (DNL™) method with us for making fusion proteins and multifunctional antibodies, and a new method of delivering imaging and therapeutic agents selectively to disease, especially different solid cancers (colorectal, lung, pancreas, etc.), by proprietary, antibody-based, pretargeting methods. We believe that our portfolio of intellectual property, which includes approximately 202 patents issued in the United States and more than 400 foreign patents, protects our product candidates and technologies. For additional information on us, please visit our website at . The information on our website does not, however, form a part of this press release.

This release, in addition to historical information, may contain forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Such statements, including statements regarding clinical trials, out-licensing arrangements (including the timing and amount of contingent payments), forecasts of future operating results, potential collaborations, and capital raising activities, involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein. Factors that could cause such differences include, but are not limited to, risks associated with any cash payment that the Company might receive in connection with a sublicense involving a third party and UCB, which is not within the Company's control, new product development (including clinical trials outcome and regulatory requirements/actions), our dependence on our licensing partners for the further development of epratuzumab and veltuzumab for non-cancer indications, competitive risks to marketed products and availability of required financing and other sources of funds on acceptable terms, if at all, as well as the risks discussed in the Company's filings with the Securities and Exchange Commission. The Company is not under any obligation, and the Company expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise.

Condensed Consolidated Balance Sheets
      June 30, 2012 June 30, 2011
Current Assets:        
Cash and cash equivalents  $ 32,838,096  $ 27,097,610
Accounts receivable, net of allowance for doubtful accounts  659,958  736,980
Inventory  415,876  289,604
Other receivables  389,002  974,331
Prepaid expenses  582,601  514,388
Other current assets  593,900  644,705
       35,479,433  30,257,618
Property and equipment, net  2,527,500  3,456,150
Value of life insurance policies  598,288  581,005
Other long-term assets  30,000  30,000
       $ 38,635,221  $ 34,324,773
Accounts payable and other accrued expenses  $ 5,594,800  $ 5,548,318
Other liabilities  1,301,212  1,134,492
Stockholders' equity  31,739,209  27,641,963
       $ 38,635,221  $ 34,324,773
Condensed Consolidated Statements of Operations
   Three Months Ended  June 30,   Year Ended June 30, 
   2012   2011   2012   2011 
License fees and other revenues  $ --   $10,037,200  $ 28,418,000  $ 10,126,550
Product sales  825,084  899,752  3,517,739  3,607,685
Research & development  137,956  178,128  798,088  975,244
Total Revenues  963,040  11,115,080  32,733,827  14,709,479
Costs and Expenses  8,515,474  8,909,090  31,859,660  33,732,141
Operating (Loss) Income  (7,552,434)  2,205,990  874,167  (19,022,662)
Interest and Other Income (Expense)  (3,466)  36,415  31,996  3,888,135
(Loss) Income before Income Tax Benefit (Expense)  (7,555,900)  2,242,405  906,163  (15,134,527)
Income Tax Benefit (Expense)  10,215  9,253  (209,785)  (109,880)
Net (Loss) Income  (7,545,685)  2,251,658  696,378  (15,244,407)
Net Loss attributable on noncontrolling interest  (29,158)  (28,042)  (113,574)  (173,986)
Net (Loss) Income attributable to Immunomedics, Inc. stockholders  $ (7,516,527)  $ 2,279,700  $ 809,952  $ (15,070,421)
Net (Loss) Income per Common Share attributable to Immunomedics, Inc. stockholders:        
Basic  $ (0.10)  $ 0.03  $ 0.01  $ (0.20)
Diluted  $ (0.10)  $ 0.03  $ 0.01  $ (0.20)
Weighted average number of common shares outstanding:        
Basic 75,540,438 75,377,741 75,481,007 75,313,349
Diluted 75,540,438 76,190,094 76,174,377 75,313,349
CONTACT: For More Information:
         Dr. Chau Cheng
         Senior Director, Investor Relations & Grant Management
         (973) 605-8200, extension 123

2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs